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RESOLVING THE DILEMMAS BETWEEN THE
PATENT LAW AND BIOTECHNOLOGY: AN
ANALYSIS OF THREE RECENT
BIOTECHNOLOGY PATENT CASES
Shaoyi Alex Liaot
I.

INTRODUCTION

Biotechnology is broadly defined to "include any technique that
uses living organisms (or parts of organisms) to make or modify products to improve plants or animals or to develop microorganisms for
specific use."1 Recombinant DNA technology, a branch of biotechnology, essentially involves isolating and replicating a genetic material, such as a desired gene, from one species and inserting the gene
into cells of another species ("host cells"). 2 The "transformed" host
cells may then be capable of producing a protein encoded for the foreign gene.3 Recombinant DNA technology makes it possible to produce proteins having therapeutic effects in marketable quantities for
treatments of diseases.
In 1980 the U.S. Supreme Court handed down a landmark decision allowing a patent for a live, human-made, and genetically-engineered bacterium in Diamond v. Chakrabarty,4 marking the beginning
Copyright @ 1995 by Shaoyi Alex Liau.
t B.S. in Biology, Jinan University, Canton, China, 1984; M.S. in Zoology, Miami University, Oxford, Ohio, 1988; LD., 1994, University of Akron, Akron, Ohio; admitted to California Bar in 1994; registered to practice before the U.S. Patent and Trademark Office.
The author wishes to thank Professor Howard A. Denemark, University of Akron, School of
Law, Akron, Ohio, for his critical comments on the original paper on which this article is based.
1. For a review of basic principles of molecular biology, see JANSS D. WATSON, MoIECULAR BiOLOGY OF Thm GEm (4th ed. 1988). See also infra note 28 and accompanying text.
2. See PEnR R. WHEALE AND Rutm M. McNALLY, GE~mrmc ENGINERING: CATASTRO-

PHE OR UTOPIA? 25-38 (1988); see infra note 28 and accompanying text; see generally JOHN D.
HAuKnNS, GENE STRucrun Arm Exi 'ssioN (1985). Deoxyribonucleic acid (DNA) is composed of four nucleotide bases, Adenine(A), Thymine (T), Cytosine (C), and Guanine (G). DNA
is a basic form of storing genetic information. Three of the four nucleotide bases constitute a
genetic code, called codon, which may be transcribed into corresponding ribonucleic acids
(RNAs), which encode for and are translated into an amino acid. Different combinations of the
four nucleotide bases form various codons which result in today's variations of genetic traits
between and among species. A gene is a functional unit of DNA. Id. at 10.
3. See infra note 28 and accompanying text.
4. 447 U.S. 303 (1980). Chakrabarty's invention was a genetically-engineered bacterium
capable of breaking down multiple components of crude oil. Id. at 305. During the examination
of the patent application, the patent examiner rejected the patent claim for the bacterium, relying
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of a biotechnology era. Since then, the biotechnology industry has
been booming.5 The number of biotechnology companies in the U.S.
increased from 93 before 1970 to about 1,330 in 1994.6 World-wide
annual sales of biotechnology-derived products had grown from zero
in 1980 to $5.9 billion in 1992 to $7.0 billion by 1993. v Sales in the
biotechnology industry have been projected to reach $50 billion in the
United States by the year of 2000.8
The biotechnology industry in the U.S. has infused 23 new drugs
into the market and holds close to 300 drugs awaiting regulatory approval. 9 Likewise, biotechnology has made enormous impacts in agriculture, environmental protection, and other fields.10 Biotechnology
has improved crops' resistance to diseases, pests, drought, and frost.11
Genetically engineered microorganisms can help to restore contaminated soil and water. 2
Despite the appealing prospects, investments in the biotechnology industry are a high risk and high cost venture. It normally takes
10 to 12 years and $259 million (per product) to develop a biotechnology-derived product and bring it to the market. 3 Because of the cuton the ground that microorganisms are "product[s] of nature." Id. at 306. The U.S. Supreme
Court disagreed and found that Congress intended the patentable subject matters to "include
anything under the sun that is made by man." Id. at 309.
5. See Dan L. Burk, Biotechnology and PatentLaw: FittingInnovation to the Procrustean Bed, 17 RUTGERS CoMPUER & TECH. L. 1, 15-16 (1991). (Most biotechnology finns
have appeared since 1980. Many of them are small entrepreneurial finns dedicated mainly to
the development and production of a few biological products.)
6. Hearing on the Competitiveness of the U.S. Biotechnology Industry Before the Subcomm. on Science, Technology, and Space of the Senate Comm. on Commerce, Science, and
Transportation, 103rd Cong., 2nd Sess. 18, 29 (1994). [Hereinafter, Hearing on the Competitiveness of the U.S. Biotechnology Industry] (Senator Bums briefly described the history of development in the biotechnology industry. Ms. Lisa Conte, President and Chief Executive Officer
(CEO) of Shaman Pharmaceuticals, testified before the Subcommittee. Ms. Conte presented
detailed statistics on the numbers and types of the biotechnology companies in the U.S.. Out of
the 1,300, there are 525 biotherapeutic companies, 344 diagnostic companies, 191 agriculturebiotechnology companies, and about 100 firms in the chemical and environmental segments.)
7. Hearing on the Competitiveness of the U.S. Biotechnology Industry, supra note 6, at
29.
8. Terry L. Medley, EmRtomna IssuEs IN E LICENsmnr OF VEnmr.aY BIoLOoICS PRODUCED TmRoUoH BIoTECHNoLoGY: ScmEC PoucY, STAT ES AM PROCEDURES, C886 ALIABA 155, 156, Nov. 19, 1993. (Remarks by Terry L. Medley, J.D., Director, Biologics, and
Environmental Protection, Animal and Plant Health Inspection Service, U.S. Department of Agriculture, citing a report by the Committee on Life Sciences and Health of the Federal Coordinating Council for Science, Engineering, and Technology).
9. Hearing on the Competitiveness in the US. Biotechnology Industry, supra note 6, at 3.
(Senator Hollings commented on the industry.)
10. Id.
11. Id.
12. Id.
13. Id. at 2. (Senator Bum's comments.)
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ting-edge nature of the industry, it is estimated that only 5 out of 4,000
14
compounds tested in predlinical trials make, it to human testing.
Only one of those five compounds tested in humans is approved for
sale. 15 In fact, less than one percent of the biotechnology companies
are profitable, and the industry as a whole has never had a profitable
year.1 6 For the aforementioned reasons, investors in the biotechnology industry have to be assured that their long-term interests are protected. Biotechnology patenting is a means to protect the fruits of
biotechnological inventions and the underlying investments.
Patent law is considered to play a very important role in the development of biotechnologies because a patent offers to patent owners
great economic incentives and benefits derived from the monopoly
power during a patent term.17 Patents for new products or innovations
resulting from recombinant DNA technology have issued in a wide
variety of areas, such as health care, environmental protection, and
agriculture. For example, patents have issued for bacteria, into which
foreign genes capable of degrading oil and other toxin have been introduced,"3 and for agricultural pesticidal bacteria. 9 Patents have also
issued for biological products, such as a protein called tissue plasminogen activator ("t-PA"), which can dissolve clots 20in blood vessels
and has a therapeutic effect on heart-attack patients.
However, several recent court decisions, mainly from the federal
district courts, on biotechnology patent disputes are likely to generate
concerns in the biotechnology industry. These decisions manifest
some internal friction and dilemmas between the fundamentals of pat14. Hearing on the Competitiveness in the U.S. Biotechnology Industry, supra note 6, at
56. (Testimony by Mr. Mark Skaletsky, CEO of GelTex Pharmaceuticals.)
15. Id. (Regulatory approval processes take about 7 years.)
16. Id. at 18. (Ms. Lisa Conte's testimony. The reasons for the industry showing consistent loss include lack of a commercialized product and high-capital allocations into research and
development.)
17. Burk, supra note 5, at 22. A patent grants a patent owner a right to exclude others
from selling, using and making the patented product. 35 U.S.C. § 271 (1952), see infra note 46
and accompanying text. See also Lynn H. Pasahow, PATENT AND TRADE SEcRr Biomcivo.,oGY LHrATioN, 886 ALI-ABA 37,39-40(1993). (Cetus Co., the owner of patents for polymerase chain reaction (PCR), sold the patented technology to Hoffmann-LaRoche Co. for $330
million.)
18. See e.g., U.S. Patent No. 4,535,061 (entitled Bacteria capableofdissimulation of environmentally persistent chemical compounds).
19. See e.g., U.S. Patent No. 5,002,765 (entitled Cloning and expression ofBacillus thur-

ingiensisgene toxic to beetles of the order Coleoptera).
20. U.S. Patent No. 4,752,603, No. 4,766,075, No. 4,853,330. The patents for t-PA are the
subject of an infringement action in Genentech, Inc. v. Wellcome Foundation, Ltd., 14
U.S.P.Q.2d 1363 (D.Del. Mar 8, 1990) (No. Civ. A. 88-330, CIV. A. 89-407-JJF) (partial summary judgment); 798 F. Supp. 213 (D.Del. 1992), rev'd by 29 F.3d 1555 (Fed. Cir. 1994). See
infra note 159 and accompanying text.
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ent law and the application of biotechnology. Section I of this article
is an introduction.' Section II illustrates some basic concepts of recombinant DNA technology. Section III of this article briefly reviews
the patent law concerned. In particular, this Section introduces basic
principles of patent infringements and the application of the doctrine
of equivalents.
Section IV discusses three patent infringement cases related to
patents for biological products and the process of making the products.
The first case, Hormone Research Foundation v. Genentech, Inc.,2 1
concerns an issue of whether an accused product, made by recombinant DNA technology, infringes patents covering a similar product is
made by a conventional technology. A potential finding of infringement under the doctrine of equivalents in Hormone Research will prohibit anyone else from making the accused product by recombinant
DNA technology. The second case, Scripps Clinic & Research Foundation v. Genentech, Inc.,' raises a similar issue of whether an accused product, which is made by recombinant DNA technology and
has better qualities, infringes patents of the same product of less purity
and potency, which is made by a conventional technology.
The final case, which will be discussed extensively, is
Genentech, Inc. v. Wellcome Foundation, Ltd..23 The case raises a
serious issue of whether the application of the doctrine of equivalents
restrains improvements of patented biological products or the
processes of making the products by a third party, who is neither a
patent owner or licensee. In the recent Wellcome decision, the Federal
Circuit Court of Appeals reversed the trial court's decision and defeated the plaintiff's assertion of infringement under the doctrine of
equivalents. 4 The issues presented in these three cases illustrate the
dilemmas in which the application of the patent law, particularly the
doctrine of equivalents, may actually restrain the improvement and
advancement of biotechnology. In addition, all accused products in
the three cases are biotechnology-derived products which have important therapeutic effects to human diseases, some of which can be lifethreatening or fatal.
21. 708 F. Supp. 1096 (N.D.Cal. 1988), vacated and remanded,904 F.2d 1558 (Fed. Cir.
1990), cert. dismissed, 499 U.S. 955 (1991).
22. 666 F. Supp. 1379 (N.D.Cal. 1987), (partial summary judgment); 678 F. Supp. 1429

(N.D. Cal. 1988), (partial summary judgment); 707 F. Supp. 1547 (N.D. Cal., 1989), (summary
judgment); 724 F. Supp. 694 (1989); aff'd in part,rev'd in part, vacated in part,remanded by
927 F.2d 1565 (Fed. Cir. 1991).

23.

14 U.S.P.Q.2d 1363 (D.Del. Mar 8, 1990) (No. Civ. A. 88-330, CIV. A. 89-407-JJF)

(partial summary judgment); 798 F. Supp. 213 (D.Del. 1992), rev'd by 29 F.3d 1555 (Fed. Cir.

1994).
24. Infra note 184 and accompanying text.
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Section V discusses the dilemmas arising from the decisions surrounding the three cases and the ramifications arising from the recent
Wellcome decision as to the methodology of analysis under the doctrine of equivalents. The Federal Circuit Court of Appeals in
Wellcome appears to favor non-patent owner's rights in a product,
which has profoundly enhanced properties other than the patented
product at issue.2 5 Arguably, the recent Wellcome holding may have
placed a heavier burden upon the plaintiffs to prove infringement
under the doctrine of equivalents in biotechnology patent cases. This
Section also discusses views from other commentators concerning the
likely solutions to the dilemmas between patent law and biotechnology, and includes a brief comment about the real versus perceived
restraining effects of the doctrine of equivalents on biotechnology.
Section VI is a conclusion. In view of the short history of biotechnology patenting, dating back to 1980, any hasty legislative or
judicial modification of the patent law, particularly the doctrine of
equivalents, to better fit the new and advanced biotechnology appears
to be premature. In the meantime, the Federal Circuit Court of Appeals continues its endeavor of refining the methodology of analysis
under the patent law, particularly under the doctrine of equivalents.
The recent case law history has indicated the Federal Circuit Court has
been attempting to resolve the dilemmas between the patent law and
biotechnology. The recent Wellcome decision exemplifies such
attempt. This article concludes that it is wise to allow time for the
judiciary to develop a line of case law in the area of biotechnology
patenting.
II.

BASIC CONCEPTS OF RECOMBINANT

DNA

TECHNOLOGY

"Genetic engineering is the manipulation of heredity or the hereditary material."2' 6 Recombinant DNA technology has been one of
several fundamental innovations in genetic engineering since World
War ]I.27
The basic technique of recombinant DNA technology involves
isolating a desired gene, or a DNA fragment, and reconnecting the
desired DNA to a DNA vector, which is normally a circular DNA and
capable of self-replication inside host cells.2 8 The process begins with
25. Id.
26.

WHEALE AND MCNALLY, supra note 2, at 19.

27. Id. at 20.
28. TERENcE A. BROWN, EssENTIAL MoLEcutAR BIOLOGY, Volume I, A Practical Approach. 1-2 (1991). A plasmid found in bacteria is one type of DNA vector used. WHEAE AND

McNALLY, supra note 2, at 29-30. Another type of DNA vector is viruses. Id.
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the use of one type of enzyme, called restriction endonuclease, which
cuts the desired gene at specific points of the DNA sequence from
cells.2 9 The circular DNA of the vector is also cut by the enzyme.
Another enzyme, called ligase, can re-connect the cleaved desired
DNA fragment with the cut vector DNA to form a recombined circular
DNA.3" The recombined DNA is then introduced into host cells, such
as bacterial cells, which are capable of reproducing large quantities of
the desired gene's products, which are usually proteins.3 1 For example, a human protein, known as human Factor VIII:C, has been successfully produced in baby hamster kidney cells using recombinant
32
DNA technology.
III. BRIEF REVIEW OF APPLICABLE PATENT LAW
The enactment of Patent statutes is expressly authorized by the
U.S. Constitution "[to promote the Progress of Science and useful
Arts, by securing for limited Times to ... Inventors the exclusive
Right to their respective... Discoveries. '33 The first Patent Act was
enacted in the second session of the Congress in 179034 and the current patent statutes are amendments based upon the Patent Act of
1951. 35
The patent system was established to fulfill two primary goals. 6
First, the patent system encourages disclosure of an invention to the
public because the patent statutes require a full and clear description
of the invention in a specification of a patent which will be published
when issued.37 In return, the patent owners are granted rights to exclude others from making, selling, and using the patented invention
during the patent term.38 The current patent term for utility patents is
29. Wl-ALE AND McNAI.y, supra note 2, at 5.
30. BROWN, supra note 28, at 5.
31. Id. at 1-2.
32. See Scripps Clinic & Research Foundation v. Genentech, Inc., 927 F.2d 1565 (Fed.
Cir. 1991), rev'g 666 F. Supp. 1379 (N.D. Cal. 1987). Human Factor VIII:C plays an important
part in a blood clotting process. Thus, Factor VIII:C has a therapeutic effect on patients with

hemophilia. See infra note 132 and accompanjing text.
33. U.S. CoNsr. art I, § 8, cI 8.
34. Act of April 10, 1790, ch. 7, 1 Stat. 109 (repealed 1793).
35. Patent Act of 1952, Pu.L. No. 82-593,66 Stat. 792 (codified as amended at 35 U.S.C.
§§ 1-376 (1989)).
36. Harold C. Wegner, Equitable Equivalents: Weighing the Equities to DeterminePatent
Infringement in Biotechnology and Other Emerging Technologies, 18 RuTOERs COMPUTER &

TECH. L.J. 1, 5 (1992), Burk, supra note 5; Michael S. Greenfield, Note, Recombinant DNA
Technology: A Science Strugglingwith the PatentLaw, 44 STAN. L. REv. 1051, 1058-1059 (the
author explains an incentive theory and a disclosure theory in detail).
37. 35 U.S.C. § 112 (1975).
38. 35 U.S.C. § 271(a) (1952).
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seventeen years from the date of issuance.3 9 Secondly, the disclosure

of an invention and the enormous benefits to patent owners will presumably stimulate more ideas and "the eventual development of further significant advances in the art."' In the meantime, the benefits
offered to patent owners will likewise presumably foster industrial development in advanced technologies, such as biotechnology.4

In order for an invention to be patentable, the invention must be
patentable subject matter.42 It must be "useful,"'4 3 "novel,"'
and
"non-obvious" to a person of ordinary skill in the art.4" During the
patent term, anyone who makes, uses, or sells the patented invention
without authority infringes the patent.4 6 The remedies for a patent

owner in an infringement suit include damages for past patent infringements47 and an injunction against future infringements.48
A.

LiteralInfringement

In an action for patent infringement, a patentee has the burden of

proving infringement by a preponderance of evidence.4 9 There are
39. 35 U.S.C. § 154 (1988). Patents are generally categorized into three groups, utility
patents, plant patents, and design patents. 35 U.S.C. §§ 101 (1952), 161 (1954), 171 (1952).
The terms of utility and plant patents will be changed to 20 years, measured from the date of
filing the application. 59 Federal Register 237 (1994)(to be codified at 37 CFR Parts 1 and 3).
The new term will go into effect on June 8, 1995. Id. Current patent terms are measured from
the date of patent issuance. The term of design patents remain the same, fourteen years. Id. 35
U.S.C. § 173 (1982).
Utility patents broadly include patents for a process, machine, manufacture, or a composition of matter. See 35 U.S.C. § 101 (1952).
40. Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 481 (1974).
41. Wegner, supra note 36, at 5.
42. 35 U.S.C. § 101 (1952). Patentable subject matters include "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement
thereof. . ." Id.
The format of a patent mainly consists of: 1) title of the invention, 2) brief summary of the
invention, 3) detailed description, and 4) claim or claims. 37 C.F.R. § 1.77 (1983). Only the
claim(s) defines the extent and the scope of the invention. 35 U.S.C. § 112 (1975).
43. 35 U.S.C. § 101 (1952).
44. 35 U.S.C. § 102 (1975). The title of this section is "Conditions for patentability; novelty and loss of right to patent." Id.
45. 35 U.S.C. § 103 (1984). This section partly reads: "[a] patent may not be obtained...
if the differences between the subject matter ...and the prior art are such that the subject matter
as a whole would have been obvious at the time of the invention was made to a person having
ordinary skill in the art to which the subject matter pertains.. ." Id.
46. 35 U.S.C. § 271(a) (1952).
47. 35 U.S.C. § 284 (1952).
48. 35 U.S.C. § 283 (1952).
49. Morton International, Inc. v. Cardinal Chemical Company, 5 F.3d 1464, 1468 (Fed.
Cir. 1993)(citing SmithKline Diagnostics, Inc. v. Helena Labs. Corp., 859 F.2d 878, 889 (Fed.
Cir, 1988); reh 'g denied, reh 'g, en banc, denied, cert. granted, 113 S. Ct. 1967 (on the issue of
mootness) (1993)).
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two steps in proving infringement.5 ° First, a court construes the patent
claims at issue to determine their meaning, or limitations.5 1 The claim
interpretation is a question of law. 2 Secondly, a fact-finder has to
decide "whether each limitation in the properly construed claims is
found, either literally or equivalently, in the allegedly infringing"
product. 3 If an accused product is found to literally include every
element of a claim in a patented invention, a literal infringement has
occurred. 54
However, a defendant can invoke a defense under the reverse
doctrine of equivalents if a literal infringement is found. The reverse
doctrine of equivalents, which is derived from the famous Graver
Tank & ManufacturingCo. v. Linde Air Products Co.,5" states that an
accused product may avoid infringement even if it is within the literal
words of the claim, if it is "so far changed in principle from a patented
article that it performs the same or similar function in a substantially
different way."56
If an accused product does not include every element of the claim
in a patented invention, the accused product can still be found to infringe the patented invention under the doctrine of equivalents if it
"performs substantially the same function in substantially the same
way to obtain substantially the same result ("function-way-result"
57
test)."

50. Morton International,5 F.3d at 1468.
51. Id., (citingFonar Corp v. Johnson & Johnson, 821 F.2d 627,631 (Fed. Cir. 1987), cert.
denied, 484 U.S. 1027 (1988)).
52. Morton International,5 F.3d at 1468. The standard of review for a question of law is
de novo on appeal. Id.
53. Id.
54. Id. (citing Envirotech Corp. v. Al George, Inc., 730 F.2d 753, 758 (Fed. Cir. 1984)).
See generally, Wegner, supra note 36. See also generally, Ronald E. Larson, Balancing the
Competing Policies Underlying the Doctrine of Equivalents in PatentLaw, 21 AIPLA Q.J. 1

(1993).
55. 339 U.S. 605, 608-609 (1950). Scripps Clinic & Research Foundation v. Genentech,
Inc., 927 F.2d at 1581 (citing Graver Tank, 339 U.S. at 608-609). lnfra note 146 and accompanying text.
56. Graver Tank, 339 U.S. at 608-609 (emphasis added).
57. See generally Id. Graver Tank & NFG. Co, Inc. v. Linde Air Product, 339 U.S. 605,
608 (1950)(citing Sanitary Refrigerator Co. v. Winters, 280 U.S. 30, 42 (1929)).
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B.

Infringement Under the Doctrine of Equivalents
1. The Famous Graver Tank Case

The doctrine of equivalents is a judicially-developed rule whose
origin can be traced back to more than a century ago.5 8 The case,
Graver Tank & Manufacturing Co. v. Linde Air Products Co.,59 is the
most recent case where the U.S. Supreme Court actually applied the
doctrine of equivalents and upheld the lower court's finding of infringement.6 ° In Graver Tank, the patent at issue was for an electric
welding flux. The patent claims for the flux composition included
essentially a combination of alkaline earth metal silicate and calcium
fluoride. 61 However, the actual formulation of patentee's products
contained two alkaline earth metal silicate, and silicates of calcium
and magnesium. Defendant's accused product formula substituted
silicates of calcium and manganese for silicates of calcium and
magnesium. 62
Because a determination of equivalence is a question of fact, the
majority in Graver Tank held that the trial court's finding of infringe63
ment under the doctrine of equivalents was not clearly erroneous.
The trial court judge found that the accused product formula was "substantially identical in operation and in result" after hearing expert testimony, visiting laboratories, viewing actual demonstrations and
various motion pictures of welding operations.6' The Court emphasized that the doctrine was intended to protect patentees from pirating
by potential infringers who design an infringing product around the
patented invention while avoiding a literal infringement.65
The dissenting justices in Graver Tank criticized the majority for
expanding the scope of the patent claims, contrary to the underlying
principle of a patent.6 6 The dissenting justices noted that the patentee
58. GraverTank, 339 U.S. at 608 (1950). Justice Jackson in his majority opinion noted
that the doctrine originated "almost a century ago in the case of Winans v. Denmead, 56 U.S. (15
How.) 330 (1853) . . ." Id.
59. 339 U.S. 605 (1950).
60. Wegner, supra note 36, at 26-27. InGraverTank, the Court cited Sanitary Refrigera-

tor Co. v. Winters, 280 U.S. 30 (1929). In Sanitary Refrigerator,the Court found that an accused device had only minor differences from the patented invention and found infringement
under the doctrine of equivalents. Id.
61.

Graver Tank, 339 U.S. at 605-606.

62.
63.
64.
65.

Id.
Id. at 612.
Id. at 611.
Id at 608.

66. Graver Tank, 339 U.S. at 614. The dissenting Justices indicated that the holding in
White v. Dunbar, 119 U.S. 47, 51 (1886), "forbids treating a patent claim 'like a nose of wax,
which may be turned and twisted in any direction, by merely referring to the specification, so as
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disclosed silicate manganese in the specification of the patent and
failed to include it in the patent claims.67 An unscrupulous use of the
doctrine is "unjust to the public," which is entitled to know the limits
and boundaries of the patent claims. 8
2. Modem Case Law On The Methodology of Analysis
Under The Doctrine of Equivalents
In 1982 the Federal Circuit Court of Appeals was established to
have exclusive appellate jurisdiction over patent disputes.6 9 Since the
most recent U.S. Supreme Court decision concerning the doctrine of
equivalents dates back to 1950 in Graver Tank, the Federal Circuit
Court of Appeals has effectively become the sole authority on any
issue arising from the doctrine of equivalents. 70 As such, the Federal
Circuit has continued its efforts to refine the methodology of analysis
under the doctrine, particularly in light of new and advanced
technologies.
In 1987 a divided Federal Circuit Court in Pennwalt Corp. v.
Durand-Wayland, Inc.71 issued an opinion en banc, establishing a
standard of analysis for the doctrine.72 Under the Pennwalt analysis, a
court first interprets the patent claims and determines their elements or
limitations. 73 Then, a plaintiff is required to show the presence of
every element or its substantial equivalent in an accused product in
order to prove infringement under the doctrine of equivalents. 74
In 1990 the three circuit judges in Wilson Sporting Goods Co. v.
Dunlop Slazenger Corp.75 established a method of determining
whether prior art restricts the permissible range of equivalents of what
to make it include something more than, or something different from what its words express'
..

" Graver Tank, 339 U.S. at 614.

67. Id. at 616. The dissenting Justices suspected that the patentee did not include the
silicate manganese in the claims probably due to the fact that the same chemical was similarly
used in an expired patent. See Id.
68. Id. at 614.
69. The establishment of the Federal Circuit Court of Appeals was intended to eliminate
inconsistent decisions among circuit courts on patent cases. Atlantic Thermoplastics v. Faytex
Corp., 974 F.2d 1279,1281 (Fed. Cir. 1992), (Judge Newman briefly reviewed the history of the
Federal Circuit Court of Appeals in its dissenting opinion on the denial of rehearing en band).
70. See supra note 60 and accompanying text.
71. 833 F.2d 931 (Fed. Cir. 1987), en banc; cert. denied, 48 U.S. 961 (1988).
72. ld Seven circuit judges joined the majority opinion, four judges joined the dissent-inpart opinion, one judge filed an additional view and one judge filed a commentary.
73. See Morton International.5 F.3d at 1468. See supra note 51 and accompanying text.
74. Pennwalt, 833 F.2d at 935 (citing Lemelson v. U.S., 752 F.2d 1538, 1551 (Fed. Cir.
1985)).
75. 904 F.2d 677 (Fed. Cir. 1990); cert. denied, 498 U.S. 992 (1990).
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is literally claimed in a patent.7 6 Wilson Sporting Goods suggests that
a court construct a hypothetical claim that is sufficiently broad in
scope to literally cover the accused product. 77 The inquiry then becomes whether the hypothetical claim would have been allowed by the
Patent and Trademark Office over the prior art.78 If the court finds
that the hypothetical claim would not have been allowed, the plaintiff
would not be permitted to obtain that coverage of scope under the
doctrine of equivalents. 79 However, in a 1994 decision, three other
circuit judges of the same court ruled that the "hypothetical claim"
analysis is not mandatory, but an alternative means to the analysis
80
under the doctrine of equivalents.
3.

Two Conflicting Public Policies Underlying The
Doctrine

The first policy concern is fair notice to the public." The public
is entitled to know what the metes and bounds of the patent claims are,
so that other parties can avoid infringement and design around the
patented invention.82 The dissenting opinion in Graver Tank might
have been a representation of the first policy concern. 83 The second
policy concern emphasizes the patent owner's rights under the patent
protection. The patentee should not be deprived of the benefits of
the patent because the competitors appropriate the essence of the patented invention and avoid infringement by simply avoiding the literal
languages of the claims.8 5 The majority's opinion in Graver Tank
seemingly addressed the second policy concern favorably and stressed
the importance of a patent owner's implicit right under the patent.8 6 A
commentator observed that the origin of the doctrine of equivalents is
76. Id. at 684. "Prior art is the existing body of technical information against which the
patentability of an invention is judged." MANUAL OF PATENT EXAMINNG PROCEDURE (M.P.E.P.)

§ 2185 (1993).
77.

Wilson Sporting Goods, 904 F.2d at 684.

78. Id.
79. Id.
80. Conroy v. Reebok International, Ltd., 14 F.3d 1570, 1576 (Fed. Cir. 1994). This is an
infringement case involving a patent entitled "Athletic Armor and Inflatable Bag Assembly."'

81.

London v. Carson Pirie Scott & Co., 946 F.2d 1534, 1538 (Fed. Cir. 1991); see Larson,

supra note 54, at 28.
82. See Larson, supra note 54, at 28.

83. See Graver Tank, 339 U.S. at 614 (J. Black, dissenting), see also supra note 68 and
accompanying text.
84. See Larson, supra note 54, at 5, 25-28.

85. London v. Carson Pirie Scott & Co., 946 F.2d, at 1538; Larson, supra note 54, at 26.
86.

Graver Tank, 339 U.S. at 608. See supra note 65 and accompanying text.

COMPUTER & HIGHTECHNOLOGY LAW JOURNAL

240

[Vol. 11

equitable in nature.17 He suggested that the doctrine only be applied
when a patentee can demonstrate an equitable need for its application.88 A determination of equivalence without consideration of equity will result in uncertain boundaries of the patent protection. 89
Such uncertainty will be likely to discourage competitors from research near the bounds of the protection for the patent.9 °
4. The Defense of Prosecution History Estoppel
An alleged infringer with an accused product is not without defenses against the doctrine of equivalents. The infringer, before or
after a finding of equivalence, can invoke a prosecution history estoppel defense.9 1 Under the estoppel, a patentee cannot "recapture
through equivalence certain coverage [of the patent claims] given up
during prosecution."'92 During the prosecution of a patent application,
an applicant may have to amend the original application or add certain
limitations to narrow the scope of a claim. The amendment often
serves to avoid a rejection by a Patent Examiner that the claim was too
broad and encompassed prior art.93 "That is not to say, however, that
whenever a limiting amendment or argument is made during prosecution, the patentee loses all coverage between what the claims literally
cover and what they would have covered prior to the amendment or
argument." 94 Thus, a patentee cannot later in an infringement suit argue that the patent should be interpreted "as if limitations added by
amendment were not present."9 5
87. Wegner,supra note 36, at 7-15. The author in Section II of the article traces the origin
and the development of the doctrine of equivalents by reviewing earlier cases, one of which dates
back to 1813. Id.
88. Id. at 5.

89. Id.
90. Id.
91. Hormone Research Foundation, Inc. v. Genentech, Inc., 904 F.2d 1558, 1564 (Fed. Cir.
1990), quoting Loctite Corp v. Ultraseal Ltd., 781 F.2d 861, 870 (Fed. Cir. 1985). A prosecution

history is simply the record of activities of a patent application in the Patent and Trademarks
Office, where the Patent Examiner's rejections and objections are recorded and the responses
from the applicant are also recorded. See 35 C.F.R. §§ 11.01-11.06; 35 C.F.R §§ 1.101-1.132
(1994).
92. Hormone Research, 904 F.2d at 1564.
93. 37 C.F.R. §§ 1.111-1.132 (1994).
94. Hormone Research, 904 F.2d at 1564.
95. Townsend Engineering Co. v. Hitech. Co., Ltd, 829 F. 2d 1086, 1090-1091 (Fed. Cir.
1987). The court reasoned that:

"[h]aving added [claim] limitations to avoid the device disclosed in the prior art,
Townsend is barred by prosecution history estoppel from interpreting his claim as
broadly as the claim originally filed ...Townsend is now precluded from con-

tending that the accused device
[Townsend's] patent."

Id. at 1091.

. . .

is equivalent to the invention claimed in
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However, any amendment or argument used by the patentee during the prosecution does not automatically estop a patentee from later
recapturing the claim coverage given up.96 The limiting effect of any
such amendment or argument, dependent upon their nature and pur97
pose, may have "a spectrum ranging from great to small to zero."1

IV. Tm THREE BIoTEcHNoLoGY

PATENT INFRINGEMENT CASES

The first case, Hormone Research Foundation v. Genentech,98
presents a patent law dilemma where an accused product, which is
made by a recombinant DNA method and has a slightly different molecular structure, can potentially infringe a patented product made by a
conventional method under the doctrine of equivalents. The second
case, Scripps Clinic Foundationv. Genentech,99 presents a similar patent law dilemma where an accused product made by a recombinant
DNA method can infringe a patent covering the same product of less
purity and potency, which is isolated by a conventional method. The
final case, Wellcome Research Foundationv. Genentech,10 0 illustrates
a serious patent law dilemma where the application of the doctrine of
equivalents can actually restrain improvements of a patented biological product by a third person who is neither a patent owner nor a
licensee.
A. Hormone Research Foundationv. Genentech, Inc. 01°
The case presents a patent law dilemma: an accused product can
potentially infringe a patented product made by a conventional method
under the doctrine of equivalents, even when the accused product has
a slightly different molecular structure and is made by a recombinant
DNA method. The patent at issue claims human growth hormone
(HGH) and its chemical synthetic process known as "Solid Phase Peptide Synthesis."' 2 When applying for the patent, the patentee mistakenly believed that the structure of the patented polypeptide (a protein)
96. Hormone Research, 904 F.2d at 1564.
97. Id. (citing Hughes Aircraft Co. v. U.S., 717 F.2d 1351, 1362-63 (Fed. Cir. 1983)).
98. 708 F. Supp. 1096 (N.D.Cal. 1988), aff'd in part,vacated in partand remanded, 904

F.2d 1558 (Fed. Cir. 1990), cert. dismissed,499 U.S. 955 (1991).
99. 666 F. Supp. 1379 (N.D.CaI. 1987), (partial summary judgment); 678 F. Supp. 1429
(N.D. Cal. 1988), (partial summary judgment); 707 F. Supp. 1547 (N.D. Cal., 1989), (summary
judgment); 724 F. Supp. 690 (1989; aff'd in part,rev'd in part, vacated in part,remanded by

927 F.2d 1565 (Fed. Cir. 1991).
100. 14 U.S.P.Q.2d 1363 (D.Del. 1990) (partial summary judgment); 798 F. Supp. 213
(D.Del. 1992), rev'd by, 29 F.3d 1555 (Fed. Cir. 1994).
101. 708 F. Supp. 1096 (N.D.Cal. 1988), aff'd in part vacated in part,and remanded, 904
F.2d 1558 (Fed. Cir. 1990), cert. dismissed, 499 U.S. 955 (1991).
102. Hormone Research Foundation v. Genentech, 904 F.2d 1558 (Fed. Cir. 1990).
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was the structure of the naturally occurring HGH. 0 3 It was later discovered that the amino acid sequence of the patented polypeptide dif04
fers from the one of the natural HGH.
Defendant Genentech made the accused product, Protropin, by a
recombinant DNA method.10 5 The amino acid sequence of Protropin,
like the natural HGH, differs slightly from the patented polypeptide at
issue." 6 Protropin has an amino acid sequence almost identical to the
natural HGH, but with one additional amino acid at the amino end of
the sequence. 1 7 By using recombinant DNA technology, Genentech
has been able to produce Protropin (HGH derivative) in marketable
quantities for use in the treatments of human growth deficiencies. 0 8
In ruling on a motion for summary judgment on the issue of literal infringement, the trial court examined the patent's specification. 10 9 The court found that the scope of plaintiff's patent claims
only encompassed chemical substances having the structure identical
to the one displayed in the patent claim, which differed from the accused product and the natural HGH." 0 The trial court held that there
was no literal infringement of plaintiff's patented product. 1 '
After finding no literal infringement, the trial court proceeded to
examine the prosecution history of the patent application. The court
found that the patentee surrendered the coverage of natural HGH or
HGH derivatives in its claims during the patent application prosecution. ' 2 During the prosecution, the Examiner rejected some of the
proposed patent claims because an article published by Bewley, et al.

103.

Id.

104. Id at 1560. The patented protein sequence has 190 amino acids while the natural one
has 191. Id The natural HGH has different amino acids in positions 73, 106, and 108. Id.

105. Id. at 1560.
106.

Hormone Research, 904 F.2d at 1560.

107. Id
108.

Hormone Research, 708 F. Supp. at 1099.

109. Id at 1100-1102.
110. Hormone Research, 904 F.2d at 1563-1564. In the patent application, the applicant

specifically exhibited a structure of a polypeptide that was previously thought as the correct one
of the natural HGH and the structure of the later patented one (which also turned out to be

incorrect after the patent was issued). Id. at 1563. The patentee explained in the specification
that there were similarities between the two structures and the differences in the number and
sequence of amino acid residues. Id.
The trial court granted two motions for summary judgment for the defendant, and denied
one judgment against the defendant and all of plaintiff's cross-motions. 708 F. Supp. 1096

(N.D. Cal. 1988).
111.
112.

708 F. Supp. at 1102.
Id. at 1103-1106.
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disclosed carbaminomethylated reduced HGH. 113 The patentee, in his
two written responses to the Examiner's rejections, stated as follows:
"Claims... are specific to the structure[s] [displayed] ...The claims
are therefore limited to the structures shown in the drawings and are
not directed broadly to HGH or its derivatives. No such structure is
The trial court
disclosed in the reference [the cited article] ...,
granted a motion for partial summary judgment filed by Genentech,
holding that the prosecution history estopped the patentee from invoking the doctrine of equivalents to include the naturally occurring
HGH. is
On appeal, Federal Circuit upheld the trial court's ruling finding
no literal infringement by the accused product, although the trial court
applied an improper methodology in its reasoning." 6 However, the
appellate court reversed the trial court's holding in which the prosecu17
tion history precluded the application of the doctrine of equivalents.!
The court held that summary judgment on the application of the doctrine of equivalents under the circumstances was improper because
there were genuine issues of material fact as to the circumstances surrounding the communications between the Examiner and the patentee. 8 The appellate court noted that there might be several possible
explanations for patentee's statements to the Examiner during the
prosecution, and the patentee-was entitled to introduce extrinsic evidence to explain the statements in a trial.1 19 The appellate court remanded the case for a factual determination of the intent and the
113. Hormone Research, 904 F.2d at 1565. 35 U.S.C. § 102 (b)(1982) reads: "[a] person
shall be entitled to a patent unless,... (b) the invention was ...described in a printed publication. . . more than one year prior to the date of the application for patent in the United States."
114. 708 F. Supp. at 1104 (emphasis added).
115. 708 F. Supp. at 1102-1106. This is the First Motion for Partial Summary Judgment
filed by Genentech to determine that defendants do not infringe certain claims in the patent at
issue. Id. at 1100.
116. 904 F.2d at 1563. The trial judge interpreted the term, "corresponding," by using a

dictionary to determine what the patentee meant, when he used the term in the claims to refer to
the structure of the patented product. Id. The appellate court found that the use of dictionary
here was improper because a patentee may be his or her own lexicographer in a patent application and thus "may use terms in a manner contrary to or inconsistent with one or more of their

ordinary meanings." Id.
117.

Id. at 1566-1567.

118.

Id. at 1566.

119. Id. at 1566-1567. One of the possible interpretations is that the patentee might mean
that he surrendered only the carbaminomethylated substitutes derived from the natural HGH. Ha.
at 1566. Another plausible explanation ofthe patentee's statement or argument during the prosecution is that the cited article did not disclose the structure of the natural HGH or teach how to

make the natural HGH. Id. at 1566-1567. The patentee may argue that the cited article can not
be used as prior art under 35 U.S.C. § 102 (b). See idl at 1566.
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effects of the patentee's statements made before the Examiner.1 20 The
court instructed the trial court to determine whether Genentech's accused product is within a "legally permissible range of equivalents" if
the court later finds that prosecution history estoppel does not

apply. 121
However, the appellate court did not review the trial court's de-

1 22
nial of defendant's second motion for partial summary judgment.

In this motion, the defendant attempted to seek a ruling that defendant's recombinant DNA method of making the accused product does

not infringe upon patentee's claimed Solid Phase Peptide Synthesis
method of synthesizing the patented product.1 23 In its reasoning, the
trial court observed that the patentee did not specify in the claims what
method would be applied.' 2 a Rather, the Solid Phase Peptide Synthesis method was not claimed but only disclosed in the specification as
the patentee's "preferred embodiment of the invention. 12 5 The trial

court denied defendant's motion, holding that the claims, rather than
the specification, measure the scope of the patented invention. 126

Thus, the case presents a patent law dilemma. A finding of infringement by Protropin under the doctrine of equivalents can prevent
120. l. at 1567.
121. 904 F.2d at 1566 n. 14. The appellate court also vacated the summary judgment holding that some patent claims were not enabling because there was a genuine issue of material fact.
Id. In other words, a person with a reasonable skill in the art would not have been able to
synthesize the chemical in accordance with the teaching in the patent specification. 35 U.S.C.
§ 112 (1975). The court observed that the trial court's decision on this issue might have been
influenced by the new and advanced recombinant DNA technology method in producing the
HGH. 904 F.2d at 1568.
122. The defendant probably did not appeal the trial court's denial of the second motion for
partial summary judgment.
123. 708 F. Supp. at 1105-1106. Claim 1 of the patent claims a "method of producing
synthetic human pituitary growth hormone which comprises" three general steps, the first of
which involves forming an amino acid chain "in the sequence of natural human pituitary growth
hormone." Id. at 1098 (citing the patent Claim 1). "Claim 3 claims a method of producing a
substance having growth-promoting activity which comprises the same three steps except the
first step requires that the chain be formed in a sequence corresponding to Fig. 2 (the patented
structure) ... of the accompanying drawing." Id. at 1099.
124. 708 F. Supp. at 1106-1107.
125. IadThere may be several ways to carry out an invention. However, 35 U.S.C. § 112
requires that an inventor in the patent specification only sets forth the best mode of carrying out
the invention in full, clear, concise and exact terms. 35 U.S.C. § 112 (emphasis added).
126. 708 F. Supp. 1096, 1107 (N.D.Cal.1988) (citingEnvironmental Designs, Ltd. v. Union
Oil Co., 713 F.2d 693, 699 (Fed. Cir. 1983)). The trial court also denied plaintiff's cross-motion
on this issue. Id.
Genentech recently settled an 8-year long lawsuit against Eli Lilly & Co. for alleged infringements of its recombinant HGH. Sales of Protropin and Nutropin brought in $217 million
revenues to Genentech in 1993. Eli Lilly & Co. agreed to pay $145 million and future royalties,
Sherri Eng, Genentech Wins Patent Settlement From Eli Lilly, SAN JosE MERcURY N., Jan. 6,
1995, at Cl.
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Genentech from using, selling, and making recombinant Protropin.

Ironically, the development and production of the recombinant HGH
derivative are very crucial to making marketable quantities for use in
the treatment of growth deficiencies in humans.
B.

Scripps Clinic & Research Foundation v. Genentech,
12 7

Inc.

The case illustrates certain restraining effects of the patent law
upon the application of recombinant DNA technology. Plaintiff
Scripps owns patents which describe and claim highly purified and
concentrated human or porcine Factor VIII:C, a protein, which is isolated by an immunological and biochemical method.128 Scripps patents also claim the process of isolation and purification of Factor
VffI:C from human and porcine plasma. 129 However, defendant
Genentech was the first party who isolated the gene for Factor VIII:C
and identified the DNA sequence of the gene. 130 After more than
three years of research efforts, Genentech developed a recombinant
DNA method to produce Factor VIII:C in baby hamster kidney
13 1
cells.
Factor VIII:C is present in the bloodstream and plays an essential
part in blood clotting and wound healing. 132 One of the disadvantages
127. 666 F. Supp. 1379.
128. 666 F. Supp. at 1383-1385. Factor VIII:C in the blood stream attaches to another
similar protein, Factor VIII:RP. IL Under the Scripps patent, Factor VIII:C is obtained by
pouring large quantities or human or porcine blood plasma over monoclonal antibodies specific
to Factor VIII:RP. Id Such monoclonal antibodies have been attached to a solid phase, such as
small beads. Id. Almost all substances will pass through the solid phase while the Factor
VIII:C-Factor VIII:RP complex is attached to the solid phase. Id. Then, the Factor VIII:C is
eluted from the solid phase, being harvested and concentrated. a.
The Factor VIII:C claimed is from either human or porcine human blood. Id at 1383.
129. Id
130. 666 F. Supp. at 1383-1384.
131. Id The gene (DNA) fragment of Factor VIII:C is inserted into a plasmid, a circular
DNA molecule that replicates itself in cells. The recombined plasmid is then introduced into a
baby hamster kidney cell, which will replicate indefinitely. The hamster cells with the Factor
VIII:C gene will produce the protein, Factor VIII:C. The Factor VIII:C will then be isolated
from the hamster's cells. Id. See supra note 28 and accompanying text.
On April 18, 1986, Genentech filed an European Patent Application claiming "human Factor VIII" and the recombinant method for its production. 666 F. Supp. at 1383-1384.
132. 666 F. Supp. at 1382-1383. The blood clotting process, though not fully understood,
may be generally described as follows:
The clotting process begins when platelets in the bloodstream adhere to the site of
a wound. The platelets would be dislodged, however, unless bound in place by
strands of fibrin, an insoluble polymer. The formation of a network of fibrin from
its soluble precursor, fibrinogen, is critical to clotting. That formation is the result
of a complex series of interactions between blood proteins. Factor VIII:C is one
of the agents that activate other proteins essential to this process. A deficiency in
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of Scripps patented method is that large quantities of blood either from
humans or pigs are needed.' 3 3 Likewise, the Factor VIII:C, isolated
according to Scripps' method, may potentially carry infectious agents
from the blood donors.' 34 However, Genentech's utilization of recombinant DNA technology in making Factor VIII:C offers certain
advantages. The production of the Factor VIII:C by Genentech's
method eliminates the need for a large pool of donor's blood and the
potential risk of transmitting infectious agents from plasma donors to
35
the recipients.'
Scripps mainly claimed its invention under two types of claims,
1) product-by-process claims,'1 36 and 2) product claims.' 37 During
summary judgment, two of the issues before the trial court were: 1)
what is the scope of Scripps' patents, and 2) whether Factor VHI:C
made by recombinant DNA technology falls within the scope, hence,
whether they infringe?
In ruling for a motion for partial summary judgment, the trial
court held that a "product-by-process claim" is only infringed by an
accused product made by the same process. 1 38 The trial court found
that Factor VIII:C produced by the recombinant DNA process did not
infringe Scripps Factor VIII:C claimed in the product-by-process
claims because the accused Factor was produced by an entirely different process. 139 However, in its early research of human Factor VIII:C
and the identification of its amino acid sequence, Genentech used the
Factor VIII:C produced by Dr. Tuddenham in England who utilized
40
the same method as claimed in Scripps product-by-process claims.'
As a result, the trial court found that Genentech literally infringed the
Factor VIII:C, therefore, prevents blood clotting. A person lacking this Factor

will be exposed to a risk of hemorrhaging from even a minor wound.
Id.
133.

Id. at 1383.

134. Id. at 1384.
135. Id.
136. 666 F. Supp. at 1386. A product of invention may be defined by the process of making
it if the English language is inadequate to describe the invention. Id. "However, the invention so

defined is a product, not a process." Id., citing In re Bridgeford, 357 F.2d 679, 682 (C.C.P.A.
1966).
For example, Claim 13 of the patent claims: "Highly purified and concentrated human or
porcine VIII:C prepared in accordance with the method of claim 1." 666 F. Supp. at 1385.
137. Id at 1389. For example, Claim 24 of the patent claims: "A human VIII:C preparation having a potency in the range of 134 to 1172 units per ml and being substantially free of

Factor VIII:RP." Id. at 1385. "Potency" refers to the amount of activity in a given volume of
solution. Hormone Research, 927 F.2d at 1569 n. 4. (Fed. Cir. 1991).
138. 666 F. Supp. at 1386-1387. The trial court cited a U.S. Supreme Court decision in
1884 and other Circuit Courts' decisions. Id.
139. Id. at 1388.
140. IM at 1387.
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product-by-process claim by using the product given by Dr. Tuddenham. 141 The court held that the plaintiff was not entitled to an
"equitable" ruling on the doctrine of equivalents because a literal infringement had been found. 142
With respect to the "product claims" in the Scripps patent, the
court found that the accused recombinant Factor VIII:C infringed the
Scripps product claims, because the accused Factor VII:C is the same
as the human Factor VII:C, regardless whether Factor VIII:C is directly isolated from the plasma or is made from recombinant baby
43
hamster cells.'
On appeal, the Federal Circuit Court reversed the trial court's
ruling that the Factor VII:C produced by the recombinant DNA
method infringed the product claims of Scripps' patent as a matter of
law.'" The appellate court noted that there were genuine issues of
material fact as to the purity and potency of the accused product in
comparison with Scripps' product claims.' 4 The court added that
Genentech might be entitled to use the reverse doctrine of equivalents
1 46
as a defense.
The Federal Circuit Court also reversed the trial court's ruling
that Scripps' product-by-process claim was not infringed by
Genentech's product made by the recombinant DNA method. 4 7 The
appellate court held that the coverage of the product-by-process claim
was not limited to the product prepared by the process set forth in the
48
claims.'
However, one year later after the Scripps decision, a panel of
judges for the Federal Circuit in Atlantic Thermoplastic Co. Inc. v.
Faytex Corp.149 rejected the Scripps holding on the issue of product141. Id. at 1387-1388.
142. Id. at 1389.
143. Id. at 1391.
144. 927 F.2d at 1581.
145. Id. The patented Factor VIII:C in the patent is partly defined by its purity and its
potency (biological activity) in the product claims, as opposed to the product-by-process claims
where the product is defined by a process resulting in the product. See supra notes 136-137.
146. Id. at 1581. The court stated that the reverse doctrine of equivalent was derived from
the statement of Graver Tank, 339 U.S. 605, 608-609 (1950). Supra note 55 and accompanying

text.
147.

927 F.2d at 1583.

148. Id.
149. 970 F.2d 834 (Fed. Cir. 1992) (holding on the issue of infringement of product-byprocess claims); 974 F.2d 1279 (Fed. Cir. 1992), (dissenting opinions to the denial of rehearing
en bane); 974 F.2d 1299 (Fed. Cir. 1992) (Judge Rader's opinion concurring the denial of rehearing en bane); 5 F.3d 1477 (Fed. Cir. 1993) (remanded on issue of on sale bar).
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by-process claims. 150 The Atlantic Thermoplastic panel held that an
accused product infringes a product-by-process claim only if the accused product is made by the same process set forth in the claim.''
More importantly, the Federal Circuit twice refused to grant a rehearing en banc to reconsider the prior ruling by the Atlantic Thermoplastic panel on the issue of product-by-process claims.' 52
The Scripps decision manifest another patent law dilemma: a
finding of literal infringement against Genentech will surely preclude
Genentech from making the recombinant Factor VIII:C, which has a
better quality and potency for use in more effective and safer treatments of hemophilia patients. Likewise, a finding of infringement
will be unjust to Genentech because it was the first party whose efforts
led to the isolation of the gene for Factor VIII:C and the identification
of the DNA sequence of the gene.
C.

Genentech, Inc. v. Wellcome Foundation,Ltd.

53

The case illustrates a serious patent law dilemma where the application of the doctrine of equivalents can potentially restrain improvements of a patented biological product by a third person who is neither
a patent owner nor a licensee. The recent appellate court decision in
Wellcome may actually have resolved such dilemmas and placed a
heavier burden on plaintiffs to prove infringement under the doctrine
of equivalents in defendants' favor.
1. Background
This is a patent infringement case involving three patents (the
'603, '075, and the '330 patents) that describe and claim a protein,
called tissue plasminogen activator ("t-PA"), and its production process.' 5 4 Genentech, one of the plaintiffs, owns an exclusive license to
the '603 patent which claims human t-PA isolated and purified from
certain human cancer cells.' 5 5 Genentech is the owner of the '075 and
'330 patents at issue. The '075 patent claims a DNA isolate contain150.

970 F.2d at 838-39 n. 2. This is an infringement case of a patent, U.S. Patent No.

4,674,204, entitled "Shock Absorbing Innersole and Method of Preparing Same."
151. Id. at 845-847.

152.

974 F.2d 1299, (Judge Rader's

concurrin'g opinion to the denial of a rehearing en

banc). FED. Cn. R. 35 governs en banc hearing in Federal Circuit. A rehearing en banc is

proper when 1) it is necessary to secure uniformity of its decisions, or 2) the proceeding involves
a question of exceptional importance. Id. at 1299-1300.
153. 14 U.S.P.Q.2d 1363 (D.Del. 1990), (partial summary judgment); 798 F. Supp. 213
(D.Del. 1992), rev'd by 29 F.3d 1555 (Fed. Cir. 1994).

154. 29 F.3d 1555, 1557. The three patents are U.S. No. 4,752,603 (the '603 patent) , U.S.
No. 4,766,075 (the '075 patent), and U.S. No. 4,853,330 (the '330 patent).
155. Id at 1558-1559.
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ing human t-PA, a recombinant vector containing human t-PA DNA
sequence, and a cell culture capable of producing human t-PA through
the use of recombinant DNA technology. The '330 patent claims
the process of producing human t-PA by recombinant DNA
56
technology.'
Human t-PA is actually an enzyme which plays a very important
physiological role within the human body. Its main function is to cut
plasminogen, an inactive enzyme present in the blood, into plasmin
(active enzyme). Plasmin in turn breaks down fibrin filaments in a
fibrin network (a clot).' 5 7 Incidentally, more than ninety percent of
heart attacks in humans are caused by clots in the vessels that supply
blood to the heart muscles. 5 ' It has been found that administration of
certain dosage of t-PA to a heart-attack patient accelerates the clot
dissolving process, stops the heart attack, and minimizes damages to
the patient's body.'5 9
The protein, t-PA, is composed of 527 amino acids in length.
The stretch of the 527 amino acid sequence is commonly divided into
five regions, called domains, referred to as (1) an "F" domain, (2) an
"E" domain, (3) a Kringle 1 ["K"] domain, (4) a Kringle 2 ["K2"]
domain, and (5) a "serine protease" domain. 160 The F domain allows
t-PA to bind to fibrin, while the KI, K2, and serine protease regions
are the enzymatically active portions of the t-PA, which cleave the
6
plasminogen present in the bloodstream.' 1
The two accused products at issue are met-t-PA and FE1X proteins. Defendants Wellcome Foundation (Wellcome) produced met-tPA which contains almost an identical sequence to that of human tPA, except for one amino acid substitution. 6 ' It is contended that the
substitution causes the met-t-PA molecule to have a different secondary and tertiary folding structure, which may weaken its binding affinity to fibrin.163 In clinical trials, met-t-PA has been proven to be
156. Id.
157. 14 U.S.P.Q.2d 1363, 1365. Human t-PA is activated by a final product of the cascade
reactions that initially formed the blood clot. Id. The formation of a clot is a physiological mechanism in the human body to block broken blood vessels before the vessels are repaired. Once the
broken vessel has been repaired, the clot is no longer needed.
158. Id.
159. Id. A heart attack is mostly caused by blood clots formed in the arteries that directly
supply blood to the heart muscle. Id. The blocking of the vessels by the clots stops the circulation of blood through the affected blood vessels. Id. Failure to dissolve the clots in a timely
manner will result in heart muscle damage or death. Id.
160. 14 U.S.P.Q. 2d at 1365.

161. Id.
162. Id. at 1368. The substitution is at position 245, replacing valine by methionine. Id.
163.

Id at 1370-1371.
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associated with a lower rate of serious, life-threatening, or fatal bleeding incidents as compared with Genentech's recombinant human tPA."6 Another named defendant, Genetics Institute (Genetics), manufactured FEIX which has a deletion of eighty-one amino acids (the
entire "F domain") from human t-PA and an amino acid substitution at
the same position as that of met-t-PA. 16 5 FE1X proteins have a fortytwo minute clearance rate in the bloodstream as compared to four minutes of human t-PA's.' 6 6 Likewise, FE1X is reportedly associated
67
with less risk of uncontrolled bleeding as compared to human t-PA.1
2.

Summary Judgment

The summary judgment only involved the '603 and '075 patents.
The trial court first generally defined that the patent coverage for
human t-PA in both the '603 and '075 patents includes three elements
of limitation: 1) it must be a human t-PA or a naturally occurring
variant, 2) it must be immunologically distinct from urokinase, 16 8 and
3) it must have a specific activity of about 500,000 IU/mg or about
90,000 IU/mg.1 69 However, the Genentech '075 patent did not define
"human t-PA" produced from recombinant DNA technology by specific activity of 500,000 IU/mg, as did the human t-PA in the '603
patent claim. 170 Because the plaintiffs were unable to demonstrate
that the accused products (met-t-PA and FE1X) were naturally present
court found no literal infringement by the two
in the human body, the
7
accused substances.1 1
Thereafter, the trial court applied the three-prong test (functionway-result) in its infringement analysis under the doctrine of
equivalents. First, the court generally observed that the human t-PA in
the '603 and '075 patents stimulates the dissolution of fibrin clots by
way of enzymatic cleavage of plasminogen to plasmin.172 Finding
that both of the accused products stimulate the dissolution of fibrin
164. Id. at 1371.
165. 14 U.S.P.Q. 2d at 1369.

166. Id. A longer clearance rate of a chemical in the blood means that the chemical will
stay in the blood for a longer time before it is eliminated from the blood stream, hence the

decrease in the number of continuous infusion of a t-PA derivative to a patient. Id.
167.

29 F.3d at 1569 n. 43.

168. Three substances are able to convert inactive plasminogen into active plasmin; they are
streptokinase, urokinase, and t-PA. Streptokinase is made by bacteria and urokinase and t-PA
are naturally present in the human body. 14 U.S.P.Q.2d 1363, 1365. Only the protein, t-PA, is
relevant to the case. Id.
169. 14 U.S.P.Q. 2d at 1368.

170. 29 F.3d at 1561-1562. Neither did they so define "human t-PA" in the '330 patent. Id.
171.
172.

14 U.S.P.Q. 2d at 1369-1370.
14 U.S.P.Q. 2d at 1370.
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clots by a way of enzymatic cleavage in the fibrin, the court concluded
that the two accused products have substantially the same "function"
and achieve substantially the same "result."1 7 However, defendants
vigorously contended that the altered structures of the two accused
products behave differently than human t-PA does. 74 In light of the
altered structures in the two accused products and the different behavior for FE1X,the trial court held that there were genuine issues of
material fact as to whether the two accused products employ substantially the same "way", namely, enzymatic cleavage, to fulfill their
functions and achieve the result. 75 The issues were for the trier of
176
fact to decide.
3.

Trial Court's Final Decision

After the trial, the jury rendered a verdict finding that the two
accused products infringed all three patents at issue under the doctrine
of equivalents. 17 7 The trial court upheld the jury's decision, finding
that there was substantial evidence to support the jury finding that the
two accused products met the three-prong test.17 However, the trial
court did not elaborate extensively on the evidence in its opinion.
With respect to met-t-PA, the court noted that the sole difference between met-t-PA and human t-PA is the amino acid substitution which
is a result of "an inadvertent cloning error by Wellcome in its effort to
copy human t-PA."'179 Likewise, the trial court agreed with the jury's
finding in that FEIX comprises all three elements of limitation as the
human t-PA in the '603 patent, including the specific activity of
"about 500,000 IU/mg.' i80 The trial court indicated that the patents at
issue claim all human t-PA derivatives which retain the essential Kringle and serine protease regions. The variation of amino acids in those
two regions, as in met-t-PA and FEIX, is not relevant, but the retention of the two regions as a whole is relevant.' 8
Both defendants filed appeals thereafter. However, Wellcome
voluntarily dismissed its appeal with prejudice and announced its intention to discontinue developing a t-PA product.1 2 Plaintiffs imme173. Id.
174. Id. at 1370-1371.
175.

Id.

176. Id. at 1371.
177.
178.

798 F. Supp. at 213.
Id. at 215-216.

179. Id. at 215.
180.
181.
182.

Id. at 216.
Id. at 216.
29 F.3d at 1560.
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diately filed a motion for permanent injunction against Wellcome,
which the trial court granted. 8 3

4. The Federal Circuit Court of Appeals' Decision
In 1994, two years after the trial court decision, the Federal Circuit Court of Appeals ruled on Genetics's appeal, reversing the trial

court's decision and finding that the jury's verdict was not supported
by substantial evidence.'1 4 The Court of Appeals held that the FEIX

product does not infringe human t-PA claimed in the '603, '075, and
'330 patents under the doctrine of equivalents.18 5 In its ruling, the
Court of Appeals first determined three threshold questions related to
claim interpretation and held as follows: 18 6 (1) the specific activity

limitation, 500,000 IU/mg, for human t-PA in the '603 patent claim is
not implicit in the '075 and '330 patent claims; 18 7 (2) the 500,000

figure in the '603 patent is IU/mg, a unit measured by using'a bovine
fibrin plate assay; 188 and (3) the literal meaning of "human t-PA" in
the '075 and '330 patent claims refers to a narrow structural defini-

tion, e.g., "human t-PA produced through recombinant DNA technology but having the same structure as natural t-PA."' 189 The court

found at least four possible definitions for "human t-PA" in the '075
and '330 patent specifications, their prosecution history, and prior
art.19 The court indicated that the diverse definitions in Genentech's
183. 798 F. Supp. at 213.
184. 29 F.3d 1555.
185. Id. at 1567, 1569. However, the met-t-PA product was not at issue on appeal because
Wellcome, which made the met-t-PA product, voluntarily dismissed its appeal with prejudice. Id.
186. Claim interpretation is a question of law and the standard of review is de novo on
appeal. Morton International,5 F.3d at 1468.
187. 29 F.3d at 1561-1562. Human t-PA in the '603 patent claim is directly isolated from
human cells while "human t-PA" in the '075 and '330 patents are produced by recombinant
DNA technology. The '075 and '330 patent claims did not define human t-PA by its specific
activity measured by the bovine fibrin plate assay. Id.
The court found that there is no basis, in the specifications of the '075 and '330 patents and
the prosecution history, for reading the 500,000 IU/mg from the '603 claim into the '075 and
'330 claims. More importantly, the court noted that the 500,000 lU/mg activity is a critical
definition of purity, which separates the claimed t-PA in the '603 patent from prior arts, e.g., less
purified substances of human t-PA isolated from the blood. Id.
188. Id. at 1562-1563. The court indicated that the figure must be assigned to a specific
assay type in order to distinguish the prior art value of similar product, 266,000 lU/mg. Id.
Expert testimonies indicated that different assay types yield different figures for the same substance. Id. at 1566.
189. 29 F.3d at 1563.
190. Id The first definition is adopted by the appellate court. The second definition is a
broader structural one, e.g., "all products containing the 'essential' Kringle region, and the Serine
Protease region." Id. The third possible definition has an even broader scope, e.g., "all products
containing just the enzymatically active portion, the Serine Protease portion." Id. at 1563-1564.
The fourth possible definition is a functional one, e.g., products "capable of catalyzing the con-
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two patents are either "a conscious attempt to create ambiguity about
the scope of the claims, or a desire" to claim a scope that is not warranted by the specifications on the part of Genentech.' 9 1
With respect to the issue of infringement upon the '603 patent,
the court noted that the only probative testimony during the trial indicated that FEIX has an activity between 208,116 to 299,484 IU/mg
measured by the bovine fibrin plate assay. 192 The FEIX activity thus
fell outside the permissible range
of equivalent value for the '603 pat19 3
ent, i.e., about 500,000 IU/mg.
In the process of reviewing the infringement upon '705 and '330
patents, the Court of Appeals seemingly placed a specific, perhaps
heavier, burden upon the plaintiffs in meeting the three-prong test
under the doctrine of equivalents. The court required the evidence be
"sufficiently particularized" to meet the three-prong test. 1 94 First, the
court determined the "operative definition" of human t-PA for the purpose of equivalency analysis. 95 After looking at the intended function of the patented product "in the context of the patent, the
prosecution history, and the prior art," 1' 9 the court concluded that fibrin binding during the clot-dissolving process is a critical component
of human t-PA "function". 19 7 The operative definition of human t-PA
should have been "catalyzing the conversion of plasminogen to plasmin and binding to fibrin."19 s Expert testimonies indicated that the
fibrin binding is likewise critical to the therapeutic effects of human tPA. 199 The court found that the plaintiffs failed to present "particularized evidence" to show that FEIX functions in substantially the same
"way" as human t-PA or achieved substantially the same "results".2 0 0
Rather, the evidence from the record pointed to the contrary.
First, the FE1X fibrin binding affinity is only 40 percent of that of
version of plasminogen to plasrnin, binds to fibrin, and is classified as a t-PA based on immunological properties as set forth hereinabove." Id. at 1564. Among the four definitions, the first
one is more consistent with the practice of the U.S. Patent and Trademark Office. Id.

191.

Id. at 1564.

192.
193.
194.
195.

Id. at 1565-1566.
29 F.3d at 1566-1567.
Id. at 1567 (citing Graver Tank v. Linde Air Products, 339 U.S. at 608.)
29 F.3d at 1567.

196. Id. 1567.
197. Id. The fibrin binding is essential to reduce the risk of hemorrhaging which is caused
by lack of blood clotting around a wound in the blood vessels. See id. Likewise, the fibrin
binding is an important distinction between t-PA and two other different plasminogen activators,
urokinase and streptokinase. Id. See also supra note 112.
198. Id.

199. 29 F.3d at 1568-1569.
200. Id. at 1568. The court found that the expert testimonies about FEIX fibrin binding
were speculative, tentative, and conclusive.
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human t-PA as a result of the deletion of the eighty-one amino acids
including the entire F domain, despite the fact that fibrin-binding is
crucial to the therapeutic effects of human t-PA.201 Secondly, the substitution of an amino acid in the FE1X amino acid sequence increases
the binding affinity of FEIX, which sufficiently renders it therapeutically effective, in spite of the fact that the F domain is deleted from
FElX.20 2 Thus, the "way" of FE1X binding is not substantially the
same as human t-PA.2 3 Finally, the increase of the FEIX clearance
rate by ten times in the human body, as compared to human t-PA, is
certainly a definite indication of different and enhanced "result"
achieved by FE1X. 2° The court indicated that the mere showing of
the K2 region's role in binding for both t-PA and FE1X was not sufficient to show a substantially identical "way" to achieve substantially
the same "result," when the property and structure of FE1X have
profound differences. 205 Likewise, FE1X's decreased binding affinity
to endothelial cells, which reduces the risk of uncontrolled bleeding, is
another indicator of a different "result".20 6
Thus, the trial court's ruling in Wellcome presents a patent law
dilemma where a better therapeutic product can be found infringing a
less-effective patented product and be prevented from entering the
market. The Federal Circuit Court of Appeals effectively relieves
FE1X from a possible injunction and makes it available to the public
use for the treatment of heart-attack patients. The appellate court's
narrow interpretations of the three-prong test may actually, at least
partly, resolve the dilemma between the doctrine of equivalents and
biotechnology.
V.

RESOLOVING THE

DELEMMAs

BETWEEN THE PATENT LAW AND

BIOTECHNOLOGY

A.

The Dilemmas

The three biotechnology patent infringement cases discussed
above illustrate the existence of a certain degree of friction between
biotechnology and the intended purposes of patent law. Likewise, the
application of the doctrine of equivalents generates invisible tensions
between the patent owners and the public. The tensions are mani201.

Id. at 1568-1569.

202. Id. The F domain allows t-PA to bind to fibrin. Supra note 160 and accompanying
text.
203.
204.
205.

29 F.3d at 1568-1569.
Id.
Id.

206. Id. at 1569. Endothelial cells make up the lining of the blood vessels. Id. at 1569,
n.43.
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fested in the two conflicting public policies: protecting patent owners'
rights to their invention on the whole versus the public's entitlement to
207
know the limits of the patent claims.
In Hormone Research, the chemical structure of the patented
product differs from both the structures of natural HGH and the accused recombinant product, Protropin. Furthermore, Protropin was
made by the recombinant DNA method as compared with the conventional method claimed in the patent. Yet on remand, Protropin can
potentially be found to infringe the patented product. A finding of
infringement is likely to deter a third party who is neither a patent
owner nor a licensee from developing a recombinant DNA method for
the production of a product like Protropin, which presumably has better quality than the patented one. Likewise, an infringement ruling
will definitely prevent Protropin from reaching the consumers, or the
patients with growth deficiencies, to the public's detriment.
In Scripps, a similar dilemma to the one in Hormone Research
exits. The accused Factor VJI:C is produced by recombinant DNA
technology while the patented Factor VJII:C is isolated by a conventional means from the plasma. Although the chemical structure of the
accused Factor VIII:C is identical to the one of the patented Factor
VIIIC, the accused Factor VIII:C probably has better purity and potency than those of the patented Factor VIJI:C because of the advantages of recombinant DNA technology. In addition, recombinant
DNA technology enables companies to make a product in marketable
quantities. An adverse ruling against the defendant will certainly preclude recombinant Factor VIII:C from entering the market, and greatly
restrict the application of recombinant DNA technology.
In Wellcome, the trial court's decision in 1992 was likely to concern the biotechnology industry, conceivably, as well as the fields related to medicine. The decision would have prevented the defendants
from making, using, and selling FE1X which is a better therapeutic
product than the patented human t-PA, not considering the waste of
human efforts and monetary investments the defendants put into research and development of FElX.20 8 Likewise, a better t-PA product
means better and more effective treatments to heart-attack patients, as
in the case of FEIX. The application of the doctrine of equivalents
apparently exerts restraining effects upon the improvement of a patented biological product to the society's detriment.
207. Supra notes 81 and 84, and accompanying text.
208. 29 F.3d at 1569. Genetics defendants expended $20 million and 130 man-years to
develop FEIX. Id. at 1564, n. 24.
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In fact, defendant Wellcome voluntarily dismissed its appeal with
prejudice on the issue of infringement by its product, met-t-PA. The
plaintiffs immediately filed a motion for a permanent injunction
against Wellcome, which the trial court granted.
Thus, the potential and actual outcomes of these cases manifest
the legal dilemmas in that the patent law, particularly the doctrine
of equivalents, can actually restrain the advancement of biotechnology
to the public's detriment. The outcomes apparently contradict the underlying purposes of the patent law, e.g., to promote and advance
technologies.
B.

The Implications From The Recent Wellcome Decision

The recent 1994 Wellcome decision by the Federal Circuit Court
of Appeals will be likely to have great impacts on the biotechnology
industry. It will surely dismiss some of the concerns surrounding the
biotechnology industry, as well as the application of doctrine of
equivalents. First, a markedly improved therapeutic product with
structural alterations may be able to survive an infringement attack,
particularly under the doctrine of equivalents. Arguably, the Court of
Appeals may have placed a more specific, perhaps heavier, burden
upon the plaintiffs to satisfy the three-prong test. The court requires
that "particularized" evidence be presented to support findings under
the three-prong test.20 9
Secondly, the appellate court disagreed with trial court's broad
and generalized definitions of the terms, "function and result" when
defining human t-PA for the purpose of equivalency analysis. In its
ruling, the appellate court specifically defined and narrowed the
scopes of those terms. With respect to the "function" of human t-PA
in two of the three patents at issue, the court included a critical biochemical property of the t-PA molecule, e.g., fibrin binding.2 10
Thus, in future biotechnology patent infringement cases, plaintiffs may have to prepare to rebut any narrower interpretation of
"function" for their patented products, in order to successfully invoke
the doctrine of equivalents. Thirdly, the plaintiffs will probably have
a heavier burden to prove that an accused product behaves in substantially the same "way", whenever the accused product manifests a
markedly improved property with an altered molecular structure.2 "1
The plaintiffs may have to present some "particularized" evidence to
show how the accused product interacts with others at the molecular
209.
210.
211.

Id. at 1567 (citing Graver Tank v. Linde Air Products, 339 U.S. 605, 608.)
Id at 1567-1568.
Idat 1569.
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level.21 2 Any speculative, tentative, or conclusive evidence will not
21 3
suffice.
Finally, the appellate court seemingly narrowed the scope of the
t-PA "result" in the analysis under the three-prong test. In the lower
court, the "result" of t-PA and FE1X was broadly defined as "dissolution of fibrin clots."2 14 However, the appellate court included other
factors in the scope of FEIX "result",21 5 such as the FEIX clearance
rate in the human body and its affinity for binding to endothelial
cells.2 16 It is apparent that the effectiveness and the safety of the therapeutic products at issue become some of the elements of their "result" under the three-prong test, in addition to the generalized "result"
of dissolving clots.
C. Suggested Resolutions Of The Dilemmas By Commentators
A commentator noted that the doctrine of equivalents was strictly
based upon equitable principles before 1850.217 Any equity-free determination of equivalence will discourage competitors from doing research around the boundary of the scope of patent claims. 2 18 It is
suggested that a plaintiff show an equitable need for the application of
the doctrine and an equitable analysis should be needed after a finding
of equivalence under the "function-way-result" test.21 9 The commentator observed that Hormone Research would have been an appropriate case to apply the equitable analysis. 2 0 Although an equivalent
was found, this was not a case where the accused infringer was attempting to copy the "patented product". 221 Rather, the accused infringer was making efforts to copy a "natural product" by using
recombinant DNA technology.2 2 An infringement should not have
been found under the equitable consideration. 2
Analogizing to a division of patent classification, the plant patents, another commentator suggested that Congress classify the bio212. 29 F.3d at 1569. The court did not specify what type of scientific evidence of sufficient details would meet th proof of "particularized evidence" even though the court indicated
that a requirement of proof of specific causes for the enhanced properties may be improper when
the field of science has not had clear understanding of the causes. Id. See also id. at n. 45.
213. Idat 1568-1569.
214. 14 U.S.P.Q. 2d. at 1368.
215. 29 F3d at 1567-1569.
216. Id.
217. Wegner, supra note 36, at 7-16.
218. Id.

219. Id. at 5, 42.
220.
221.
222.

Wegner, supra note 36, at 32-33.
Id. at 33.
lId

223. Id.
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technology patents into an entirely different scheme of intellectual
property protection.2 24 This commentator opined that one should not
force either the biotechnology patents or certain patent doctrines to fit
25
into each other by making compromising modifications.
One commentator suggested that legislative intervention may be
needed to resolve the apparent dilemma between the patent law and
the rapidly developing biotechnology industries. 2 6 One of the means
to resolve the dilemma is to promulgate rules stating that the scope of
a product made or isolated from a traditional way will not encompass
22 7
the same product made by recombinant DNA technology.
This writer observes that the suggested introduction of equitable
consideration into the analysis under the doctrine of equivalents may
not be feasible, because a standard for an equitable consideration may
be too broad and vague. As a result, more ambiguity and uncertainty
will be injected into the already-muddy area of analysis under the doctrine of equivalents. While the legislative intervention may be feasible, this writer notes that it may not be wise to seek legislative
intervention and create an exception to a fairly-settled field of patent
law, whenever there is friction between the "old" law and a new
technology.
In comparison with the history of biotechnology, the doctrine of
equivalents has an origin dating back to more than a century ago,
while biotechnology patenting literally started with Chakrabarty in
1980.28 The judiciary may need more time to develop a line of case
law in the area of biotechnology patent disputes.
Finally, this writer observes that the restraining effects of patent
law, particularly the doctrine of equivalents, upon the improvement of
a patented product and upon the advancement of biotechnologies, such
as recombinant DNA technology, may be minimal. Although a third
party may be deterred from doing research on a product, which may
fall into the scope of equivalents of a patented product, a patent owner
may still be interested in making any improvement on the patented
product by using advanced technologies, such as recombinant DNA
technology. The economic incentives of maximizing profits are high
for the industry to improve existing products by using advanced technologies. New technologies bring high efficiencies and better quali224.
225.

Burk, supra note 5, at 82-85.
Id.

226. Bret Field, Note, Protein Pharmaceuticals:Altering the Scope ofProduct Patents to
Accommodate Recombinant DNA Technology, 15 HAsTmIs Comm. & ENT. L.J. 495, 518
(1993).
227. Id.
228. See supra note 4 and accompanying text.
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ties to productions. Furthermore, an improved biological product can
have more beneficial or better therapeutic effects which benefit the
society in general.
VI.

CONCLUSION

The dilemmas between the patent law and biotechnology have
manifested in several federal district decisions, which would have restrained the advancement of biotechnology, as well as, the improvements of biological products. Nevertheless, the restraining effects are
minimal.
In the meantime, the Federal Circuit Court of Appeals continues
its endeavors of refining the methodology of analysis under the patent
law, particularly the doctrine of equivalents, ever since the 1950
Graver Tank case. In 1987, an en banc decision in Pennwalt established an element-by-element equivalent analysis under the doctrine.
In 1990, Wilson Sporting Goods suggested a "hypothetical claim" alternative for the equivalent analysis. Likewise, in a recent 1994 case,
Federal Circuit ordered a rehearing en banc to decide a question of
whether a finding of patent infringement under the doctrine of
equivalents requires factors in addition to proof of the facts needed for
the three-prong test. 2 9
In Hormone Research, the trial court's refusal to apply the doctrine of equivalents because of prosecution history estoppel would
have relieved the recombinant HGH derivative from injunction and
made it available to the public. A finding of infringement under the
doctrine of equivalents will certainly prohibit the use of the recombinant Protropin by anyone else, a result which would be to the public's
detriment.
In Scripps, the appellate court correctly instructed that defendant
Genentech could use the defense of reverse doctrine of equivalents, if
the recombinant Factor VIII:C had better potency and purity than the
patented Factor VII:C in the product claim.3 0 Such instruction will
be likely to relieve the recombinant Factor VIII:C from injunction and
be made available to the public as well.
With respect to the holding on the issue of product-by-process
claims in Scripps, the ruling would have unduly restricted the use of
recombinant DNA technology to manufacture a product patented by a
product-by-process claim having a different process. Fortunately, a
229. Hilton Davis Chemical Co. v. Wamer-Jenkinson Company, No. 93-1088, 1993 WL
761179, argued on March 3, 1994 (Fed. Cir. 1994). The appellate court in Wellcome refused to
consider facts other than those needed for the three-prong test. 29 F.3d at 1569 n. 46.
230. Supra note 194 and accompanying text.
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Circuit judge panel in Atlantic Thermoplastic correctly rejected the
Scripps holding on such issue and effectively narrowed -the scope of a
product-by-process claim, to the benefit of the biotechnology industry.
Likewise, Federal Circuit responded to the conceivable concerns
from the biotechnology industry quite favorably in the recent
Wellcome case. The trial court's broad interpretations under the doctrine of equivalents would have led to an injunction against FE1X,
which has better therapeutic effects and less risk than the patented
human t-PA to heart-attack patients. The appellate court in Wellcome
wisely narrowed the three-prong test analysis under the doctrine of
equivalents and made FE1X available to the public.
Thus, recent case law history has manifested a trend in that the
Federal Circuit Court of Appeals has been endeavoring to resolve the
dilemmas between the patent law and biotechnology. The Wellcome
decision exemplifies such trend. It is wise to allow time for the judiciary to develop a line of cases in the area of biotechnology patenting.

